# Voxelotor Neurocognitive Function Study

> **NCT05228834** · PHASE3 · TERMINATED · sponsor: **Pfizer** · enrollment: 1 (actual)

## Conditions studied

- Sickle Cell Disease

## Interventions

- **DRUG:** Voxelotor Only Product in Oral Dose Form
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05228834
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-06-24
- **Primary completion:** 2022-09-30
- **Final completion:** 2022-09-30
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Data will not inform further development of Voxelotor
- **Last updated:** 2024-05-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05228834

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05228834, "Voxelotor Neurocognitive Function Study". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05228834. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*